High prevalence of acquired HIV drug resistance among gay and bisexual men on antiretroviral therapy in Surabaya, Indonesia: a call for routine genotypic surveillance
DOI:
https://doi.org/10.56294/saludcyt20252190Keywords:
HIV-1, drug resistance, molecular epidemiology, Indonesia, CRF01_AE, MSMAbstract
Introduction: HIV affects men who have sex with men (MSM) in a disproportionate way, especially in concentrated epidemics such as Indonesia. Surabaya carries the highest burden among MSM in the country. Yet, evidence on HIV-1 molecular epidemiology and drug resistance is scarce.
Methods: A cross-sectional study involved 57 HIV-1–infected gay and bisexual men on antiretroviral therapy (ART) in Surabaya during 2022–2023. Blood samples were taken for HIV-1 pol gene amplification (protease and reverse transcriptase). Sanger sequencing produced subtype data through phylogenetic analysis and RIP. Drug resistance mutations (DRMs) were assessed with IAS-USA 2023 and Stanford HIVdb v10.0.
Results: CRF01_AE dominated (82.0%), followed by subtype B (10.5%) and recombinants (7.5%). Sixteen participants had sequences that passed analysis. Five of them (31.3%, 95% CI: 11.8–58.7%) carried major DRMs: K65R (NRTI), K103N (NNRTI), and Q58E/V82A (PI). One case showed resistance to more than one drug class. Overall resistance rates surpassed both regional estimates and the WHO 10% benchmark.
Conclusions: See the corresponding section at the end of the paper.
References
1. Vega Y, Delgado E, Fernández-García A, Cuevas M, Thomson M, Montero V, et al. Epidemiological Surveillance of HIV-1 Transmitted Drug Resistance in Spain in 2004-2012: Relevance of Transmission Clusters in the Propagation of Resistance Mutations. PLoS ONE. 2015;10.
2. Schmidt D, Kollan C, Fätkenheuer G, Schülter E, Stellbrink H, Noah C, et al. Estimating Trends in the Proportion of Transmitted and Acquired HIV Drug Resistance in a Long Term Observational Cohort in Germany. PLoS ONE. 2014;9.
3. Hofstra L, Rivas ES, Nijhuis M, Bank L, Wilkinson E, Kelly K, et al. High Rates of Transmission of Drug-resistant HIV in Aruba Resulting in Reduced Susceptibility to the WHO Recommended First-line Regimen in Nearly Half of Newly Diagnosed HIV-infected Patients. Clinical Infectious Diseases. 2017;64:1092–7.
4. Buskin S, Zhang S, Thibault C. Prevalence of and Viral Outcomes Associated with Primary HIV-1 Drug Resistance. The Open AIDS Journal [Internet]. 2012;6:181–7. Available from: https://api.semanticscholar.org/CorpusId:18295603
5. Dagnra A, Vidal N, Mensah A, Patassi A, Aho K, Salou M, et al. High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lomé, Togo. Journal of the International AIDS Society. 2011;14:30.
6. Zhou Z, Wagar N, DeVos J, Rottinghaus EK, Diallo K, Nguyen DB, et al. Optimization of a Low Cost and Broadly Sensitive Genotyping Assay for HIV-1 Drug Resistance Surveillance and Monitoring in Resource-Limited Settings. PLoS ONE. 2011;6.
7. Pérez L, Alemán Y, Correa C, Fonseca C, Aragonés C, Álvarez A, et al. Antiretroviral drug resistance in HIV‐1 therapy‐naïve patients in Cuba, 2006–2011. Journal of the International AIDS Society. 2012;15.
8. Tsai H, Chen IT, Wu KS, Tseng Y, Sy C, Chen JK, et al. High rate of HIV-1 drug resistance in treatment failure patients in Taiwan, 2009–2014. Infection and Drug Resistance. 2017;10:343–52.
9. Alteri C, Svicher V, Gori C, D’arrigo R, Ciccozzi M, Ceccherini‐Silberstein F, et al. Characterization of the patterns of drug-resistance mutations in newly diagnosed HIV-1 infected patients naïve to the antiretroviral drugs. BMC Infectious Diseases. 2009;9:111.
10. Su Y, Zhang F, Liu HX, Smith M, Zhu L, Wu J, et al. The Prevalence of HIV-1 Drug Resistance among Antiretroviral Treatment Naïve Individuals in Mainland China: A Meta-Analysis. PLoS ONE. 2014;9.
11. Bennett D, Camacho R, Oțelea D, Kuritzkes D, Fleury H, Kiuchi M, et al. Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update. PLoS ONE. 2009;4.
12. Guo CX, Wu Y, Zhang Y, Liu X, Li A, Gao M, et al. Transmitted Drug Resistance in Antiretroviral Therapy-Naive Persons With Acute/Early/Primary HIV Infection: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology. 2021;12.
13. Pessôa R, Sanabani S. High prevalence of HIV-1 transmitted drug-resistance mutations from proviral DNA massively parallel sequencing data of therapy-naïve chronically infected Brazilian blood donors. PLoS ONE [Internet]. 2017;12. Available from: https://api.semanticscholar.org/CorpusId:33621723
14. Onywera H, Maman D, Inzaule S, Auma E, Were K, Fredrick H, et al. Surveillance of HIV-1 pol transmitted drug resistance in acutely and recently infected antiretroviral drug-naïve persons in rural western Kenya. PLoS ONE. 2017;12.
15. Mahapatra R, Barrett N, Psevdos G. Antiretroviral drug resistance among U.S. veterans living with human immunodeficiency virus 1. HIV & AIDS Review. 2019;
16. Khairunisa S, Megasari NLA, Rahayu R, Witaningrum A, Ueda S, Matondang MQY, et al. Detection of human immunodeficiency virus type 1 transmitted drug resistance among treatment-naive individuals residing in Jakarta, Indonesia. Infectious Disease Reports. 2020;12.
17. Djojosugito FA, Arfianti A, Wisaksana R, Siregar F, Nasronudin N, Rachman B, et al. Prevalence of major INSTI and HIV-1 drug resistance mutations in pre- and antiretroviral-treated patients in Indonesia. Narra J. 2024;4.
18. Clipman S, Solomon S, Srikrishnan A, Mcfall A, Gomathi S, Saravanan S, et al. Antiretroviral Drug Resistance in HIV Sequences From People Who Inject Drugs and Men Who Have Sex With Men Across 21 Cities in India. Open Forum Infectious Diseases. 2022;9.
19. Shi YZ, Huang H, Wang XH, Song B, Jiang TJ, Yu MR, et al. Retrospective Study on Genetic Diversity and Drug Resistance among People Living with HIV at an AIDS Clinic in Beijing. Pharmaceuticals. 2024;17.
20. Ivanda RRN, Salma D, Joanna AH, Fathin A, Athadita S, Saputri P, et al. Systematic Review of Health Emergency Policies and Their Impact on Referral Mechanisms During the COVID-19 Pandemic. Health Frontiers: A Multidisciplinary Journal for Health Professionals. 2025;3(1):53–64.
21. Damayanti NA, Putri DA, Chilau GS, Napitupulu, Kholvi IZ, Khairunnisa, et al. Optimizing Bpjs Referral Systems: A Pathway To Equitable, Sustainable Healthcare Access In Indonesia. Health Frontiers: A Multidisciplinary Journal for Health Professionals. 2025;3(1):43–52.
22. King JM, Giallonardo F, Shaik A, McGregor S, Yeung J, Sivaruban T, et al. Low HIV drug resistance prevalence among recently diagnosed HIV‐positive men who have sex with men in a setting of high PrEP use. Journal of the International AIDS Society. 2024;27.
23. Levintow SN, Okeke N, Hué S, Mkumba L, Virkud A, Napravnik S, et al. Prevalence and Transmission Dynamics of HIV-1 Transmitted Drug Resistance in a Southeastern Cohort. Open Forum Infectious Diseases. 2018;5.
24. Macdonald V, Mbuagbaw L, Jordan M, Mathers BM, Jay S, Baggaley R, et al. Prevalence of pretreatment HIV drug resistance in key populations: a systematic review and meta‐analysis. Journal of the International AIDS Society. 2020;23.
25. Sulistina DR, Martini S, Prasetyo B, Rahman FS, Adji A, Li CY, et al. A systematic review and meta-analysis of HIV transmission risk behaviors, genetic variations, and antiretroviral (ARV) resistance in LGBT populations. Journal of Public Health Research. 2024;13.
26. Budiono CE, Arif HLN, Efendi SGK, Ramadani NA, Hendrawan NF, Prakusya NLM, et al. From Sensors to Safety: IoT-Enabled Smart Helmets as a Game-Changer for Worker Protection in High-Risk Industries. Health Frontiers: A Multidisciplinary Journal for Health Professionals. 2025;3(1):30–42.
27. Budiono CE, Lukman H, Arif N, Galih S, Efendi K, Ayu N, et al. Decentralizing Healthcare Referrals: How Graph Neural Networks and Blockchain Can Bridge Gaps in LMICs for Equitable Care. Health Frontiers: A Multidisciplinary Journal for Health Professionals. 2025;3(1):99–106.
28. Ivanda RRN, Salma D, Joanna AH, Fathin A, Athadita S, Saputri P, et al. Simulation Outcomes: Impact of Health Emergency Policies on Referral Mechanisms During the Pandemic. Health Frontiers: A Multidisciplinary Journal for Health Professionals. 2025;3(1):88–98.
29. Booth C, Geretti A. Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection. The Journal of antimicrobial chemotherapy [Internet]. 2007;59 6:1047–56. Available from: https://www.ncbi.nlm.nih.gov/pubmed/17449483
30. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, et al. Antiretroviral-drug resistance among patients recently infected with HIV. New England Journal of Medicine. 2002;347(6):385–94.
31. Bennett D, Bertagnolio S, Sutherland D, Gilks C. The World Health Organization’s global strategy for prevention and assessment of HIV drug resistance. Antiviral Therapy [Internet]. 2008;13:1–13. Available from: https://doi.org/10.1177/135965350801302S03
32. Yumna NA, Fitri ANI, Putri LA, Umar M, Sayyida FL, Mustofa AD, et al. The Hidden Crisis in Healthcare: How Referral Non-Compliance Jeopardizes Patient Safety and Invites Malpractice. Health Frontiers: A Multidisciplinary Journal for Health Professionals. 2025;3(1):76–87.
33. Harahap SP, Islami TA, Alfaryzy R. Equity in Healthcare Referrals: Navigating Legal Rights and Digital Frontiers for Fair Access. Health Frontiers: A Multidisciplinary Journal for Health Professionals. 2025;3(1):65–75.
34. Manasa J, Lessells R, Skingsley A, Naidu K, Newell M, McGrath N, et al. High-Levels of Acquired Drug Resistance in Adult Patients Failing First-Line Antiretroviral Therapy in a Rural HIV Treatment Programme in KwaZulu-Natal, South Africa. PLoS ONE [Internet]. 2013;8. Available from: https://api.semanticscholar.org/CorpusId:13773885
35. Lule DB, Ssemwanga D, Kaleebu P, Tully DC. The utility of integrating nanopore sequencing into routine HIV-1 drug resistance surveillance. Microbial Genomics [Internet]. 2025;11. Available from: https://api.semanticscholar.org/CorpusId:277149087
36. Sigaloff K, Mandaliya K, Hamers RL, Otieno F, Jao I, Lyagoba F, et al. Short communication: High prevalence of transmitted antiretroviral drug resistance among newly HIV type 1 diagnosed adults in Mombasa, Kenya. AIDS Research and Human Retroviruses. 2012;28(9):1033–7.
37. Tsai H, Chen IT, Lee S, Chen Y. HIV-1 genotypic drug resistance in patients with virological failure to single-tablet antiretroviral regimens in southern Taiwan. Infection and Drug Resistance [Internet]. 2018;11:1061–71. Available from: https://api.semanticscholar.org/CorpusId:52031164
38. Fadhilah INM, Firdausy AH, Savira BH, Zalianti DA, Sefriza A, Hastari FVA, et al. Bridging the Gap: Navigating Regulations to Enhance Referral Coordination Between Puskesmas and Hospitals. Health Frontiers: A Multidisciplinary Journal for Health Professionals. 2025;3(1):15–29.
39. Wahyudi NT, Yunus M, Malang UN. Enhancing Athlete Performance with Mobile Health Applications: Benefits and Challenges. Health Frontiers: A Multidisciplinary Journal for Health Professionals. 2025;3(1):1–9.
40. Wahyuni ES, Septyasih R, Solikhah FK, Prastiwi S, Malang PK. Children’s Motor Skills Development After Puzzle Play Therapy. Health Frontiers: A Multidisciplinary Journal for Health Professionals. 2025;3(1):10–4.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Dewi Ratna Sulistina, Fitriana Kurniasari Solikhah, Mukammad Toha, Fatimah Zahra, Ronal Surya Aditya (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
